Lori James, NP
Acute Care · Columbia, TNNPI 1114065398
Payments from drug & device makers
Across 187 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$625
- Novo Nordisk$347
- Boehringer Ingelheim$236
- GSK$234
- Amgen$193
- AstraZeneca$156
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,20999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $625 |
| Novo Nordisk | 19 | $347 |
| Boehringer Ingelheim | 12 | $236 |
| GSK | 14 | $234 |
| Amgen | 11 | $193 |
| AstraZeneca | 10 | $156 |
| Pfizer | 8 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $101 |
| Johnson & Johnson(2 entities) | 6 | $99 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Abbott | 4 | $84 |
| Exact Sciences | 4 | $83 |
| Nestle Healthcare Nutrition Inc. | 4 | $77 |
| Lilly USA, LLC | 5 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 3 | $58 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Boston Scientific | 2 | $49 |
| Astellas Pharma US Inc | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Merck | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Dexcom, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Apria Healthcare LLC | 1 | $11 |
How this compares
$3,239 in reported general payments places this provider in the 85th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $86,149 |
| MounjaroTirzepatide | 58 | $67,844 |
| OzempicSemaglutide | 47 | $61,302 |
| RexultiBrexpiprazole | 13 | $32,725 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $31,314 |
| EliquisApixaban | 22 | $31,261 |
| Spiriva RespimatTiotropium Bromide | 16 | $22,744 |
| XareltoRivaroxaban | 22 | $22,558 |
| TrulicityDulaglutide | 18 | $19,135 |
| VraylarCariprazine Hcl | 12 | $16,246 |
| LinzessLinaclotide | 11 | $6,541 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $6,067 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $5,786 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $4,763 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $236 | $108,89382 claims |
| Lilly USA, LLCMounjaro, Trulicity | $72 | $86,97976 claims |
| Novo NordiskOzempic | $347 | $61,30247 claims |
| PfizerEliquis, Paxlovid | $110 | $34,07834 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $32,72513 claims |
| GSKTrelegy Ellipta | $234 | $31,31429 claims |
| AbbVieVraylar, Linzess, Synthroid | $625 | $24,57239 claims |
| Johnson & JohnsonXarelto | $99 | $22,55822 claims |
| Sanofi-aventis U.S. LLCLantus | $29 | $4,76311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 738 acute care providers in Tennessee.
Other acute care in Columbia
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Stephen MillerKnoxville$108K
- Shannon GraceNashville$57K
- Timothy BallardKnoxville$47K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
- Elizabeth DavidsonNashville$33K
- Kelly JacksonMurfreesboro$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.